Welcome! Thank you for subscribing to the Earnings360 newsletter, your daily source for quarterly earnings news and updates.
Each morning edition contains a wrap-up of today's pre-market earnings announcements and yesterday's earnings announcements after the closing bell.
Please take a moment to confirm your subscription below so we can ensure these updates reach your inbox.
Confirm Your Subscription Here
The Earnings360 Team
Wednesday's Bonus Article Why GRAIL Stock Could Be Biotech's Next Big BreakoutWritten by Bridget Bennett. Published 11/19/2025. 
Key Points - Insider buying is a reliable signal in market pullbacks, offering long-term confidence amid short-term volatility.
- Biotech stock GRAIL is one to watch, with its breakthrough cancer detection technology nearing FDA approval.
- Despite economic concerns, the American Dream is still attainable through long-term investing, saving, and strategic financial choices.
Retail investors are understandably on edge after recent market volatility. But bestselling author and Oxford Club strategist Alexander Green, in his new book The American Dream, says we're still in one of the best periods in history to build wealth—especially if you think long-term and stick to time-tested principles. According to Green, this pullback isn't as severe as it may feel. "Just last Wednesday, the Dow hit an all-time high," he noted, explaining that recent selling pressure has more to do with valuation concerns and interest-rate uncertainty than any widespread fundamental breakdown. Why the Market Pulled Back A major shift is coming to the gold market — the world's largest gold buyer is preparing to launch a new way for everyday Americans to invest in gold with a click, and when it goes live in 2026 it could unleash a wave of demand unlike anything we've seen. Garrett Goggin believes one $1.60 gold stock is positioned to be a prime beneficiary of this surge — a move where even a small price jump could mean a meaningful gain — along with several other miners set to ride the same trend. Click here to see the $1.60 gold stock and Garrett's full list of recommendations Green points to two main causes. First, investors are questioning elevated tech and AI valuations, and earnings season is bringing those expectations into sharper focus. Second, inflation data and slower hiring have tempered hopes that the Fed will cut rates in December. With the central bank maintaining a "data-dependent" stance, markets are less confident that rate relief is coming this year. Why Selling Now Might Be the Wrong Move Rather than trying to predict next week's moves, Green urges investors to zoom out. He describes himself as "a long-term optimist," noting that over time the market's trend has been upward. Short-term traders may want to exercise caution, but for long-term investors, pullbacks can be opportunities to buy high-quality stocks at more attractive prices. Insider Buying Can Point the Way One reliable signal in choppy markets is insider buying. Green says when officers and directors—people with access to non-public financial information—are putting their own money into their companies, it's worth paying attention to. He recommends tracking insider trading activity to see which stocks corporate executives are buying, not just selling. Insiders aren't always right, but their actions can be a useful signal when markets are uncertain. A Biotech Breakout to Watch: GRAIL One sector Green is focused on right now is biotech, where artificial intelligence is helping accelerate drug development and lower costs. He highlighted one company in particular: GRAIL (NASDAQ: GRAL). Spun off from Illumina, GRAIL developed the Galleri Test, which can detect more than 50 types of cancer from a single blood draw. Green has used the test himself and calls it "a good feeling" to know you're clear on so many deadly diseases—especially cancers like pancreatic that often go undetected until late stages. With FDA fast-track status and the potential for insurance reimbursement ahead, Green views GRAIL's roughly $3 billion market cap as just a starting point. The Biotech Risk—and Big Pharma's Appetite Biotech carries risk: most drugs never make it through all three phases of trials. Still, large pharmaceutical companies such as Merck (NYSE: MRK), Pfizer (NYSE: PFE), and Bristol Myers (NYSE: BMY) actively acquire promising small caps to replace expiring patents. Green pointed to Johnson & Johnson (NYSE: JNJ) as a recent example: the company invested in a private prostate cancer drug before it received FDA approval—underscoring how aggressive Big Pharma can be when clinical trials look promising. He also argues biotech is especially attractive now because healthcare is relatively recession-resistant. People still need treatment regardless of the economic cycle, and sectors like healthcare, utilities, consumer staples, and food tend to offer steadier demand—and less drama—than high-flying AI names. The American Dream Is Still Possible—But Mindset Matters Despite economic challenges, Green maintains the American Dream is far from dead. He wrote The American Dream to counter the narrative that it's out of reach, noting he was surprised to see polls showing nearly 70% of Americans believe it's no longer attainable. His view: with low-cost investment tools, no-commission trading, and abundant information, building wealth is more accessible than ever. The challenge is knowing what to do—and having the discipline to do it. He lays out a simple example: if a 25-year-old invests $190 per month in an S&P 500 index fund, they could have $1 million by age 65—tax-free in a Roth IRA. No extreme frugality required. "You could eat out, take trips, and still build wealth," Green says—as long as you save consistently and let your investments compound. Creative Solutions for Today's Housing Market Housing can feel out of reach, but Green says there are alternatives. Mortgage rates have doubled and prices are up sharply since the pandemic, but there are still ways to get started. He shares his personal story of buying two houses with no money down by working directly with motivated sellers and assuming their mortgages—a method sometimes called a "contract for deed." It may not produce a perfect home immediately, but it can help you start building equity sooner. Stay Focused on the Long Game Volatile markets come and go. What matters is how you respond. Whether it's tracking insider moves, exploring high-upside sectors like biotech, or simply believing in your ability to build a financial future, Green's message is clear: the American Dream is still within reach. Keep your focus, take the next right step, and let time and discipline do the work.
| 
